Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 2;5(5):e2214594.
doi: 10.1001/jamanetworkopen.2022.14594.

Periprocedural Outcomes Associated With Use of a Left Atrial Appendage Occlusion Device in China

Affiliations

Periprocedural Outcomes Associated With Use of a Left Atrial Appendage Occlusion Device in China

Fangju Su et al. JAMA Netw Open. .

Abstract

Importance: Left atrial appendage occlusion (LAAO) has emerged as an alternative to anticoagulation for patients with atrial fibrillation. However, the performance of LAAO among East Asian patients is unknown.

Objective: To document the procedural success rate and configurations, major adverse event rates, and antithrombotic medication regimens during and after LAAO procedures among patients in China.

Design, setting, and participants: In this cohort study, consecutive patients from 39 Chinese centers undergoing LAAO were prospectively enrolled between April 1, 2019, and October 31, 2020. Periprocedural and intraprocedural techniques and postprocedural medications were left to the surgeon's discretion. Data were analyzed from July 1 to November 1, 2021.

Exposure: LAAO for patients with atrial fibrillation.

Main outcomes and measures: The main outcomes were procedural success and complication rates periprocedure and major adverse event rates of death, stroke, systemic embolism, and bleeding events at 30 days postprocedure; the composite end point of death, stroke, and systemic embolism was also analyzed. Unadjusted and multivariable-adjusted logistic regression analyses were performed to assess the associations of periprocedural techniques (types of anesthesia, intraprocedural imaging modalities, and combined ablation procedure) with 30-day adverse events.

Results: Among 3096 enrolled participants, 1782 participants (57.6%) were men, and the mean (SD) age was 69 (9) years. Participants had a high risk of stroke (mean [SD] cardiovascular risk score, 4.0 [1.8]) and a moderate-to-high risk of bleeding (mean [SD] bleeding risk score, 2.4 [1.2]). A total of 1287 procedures (41.6%) were performed under local anesthesia, while 493 procedures (15.9%) used only fluoroscopy guidance. In 1297 procedures (41.9%), LAAO implantation was combined with radiofrequency ablation or cryoablation for atrial fibrillation. Procedural success was achieved in 3032 patients (97.9%). At 30-day follow-up, the rate of the composite end point of death, stroke, or systemic embolism was 0.52% (95% CI, 0.32%-0.84%), and the rate of any life-threatening or major bleeding was 1.23% (95% CI, 0.90%-1.68%). No significant associations were observed between the procedural success or 30-day adverse events and the types of anesthesia (general or local), intraprocedural imaging (transesophageal echocardiography, fluoroscopy, or intracardiac echocardiography), or whether a combined ablation procedure was performed or not. In centers performing at least 40 procedures per year, compared with those performing fewer than 40 procedures per year, procedural success was significantly higher (adjusted odd ratio [aOR], 1.97; 95% CI, 1.01-3.53; P = .02) and risk of life-threatening or major bleeding was significantly lower (aOR, 0.42; 95% CI, 0.21-0.87; P = .02).

Conclusions and relevance: These findings suggest that patients with a high risk of stroke and moderate to high risk of bleeding who underwent implantation of a LAAO device in Chinese centers had high rates of procedural success and low rates of short-term ischemic and bleeding events.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Serruys reported receiving personal fees from Sahajanand Medical Technologies, Novartis, Merillife, Xeltis, and Philips/Volcano outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Post–Left Atrial Appendage Occlusion (LAAO) Antithrombotic Medications
AF indicates atrial fibrillation; CSC, Chinese Society of Cardiology; DAPT, dual antiplatelet therapy; ESC, European Society of Cardiologists; HAS-BLED, hypertension, abnormal kidney or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (ie, aged >65 years), and using drugs or alcohol concomitantly; NOAC, novel oral anticoagulant; and SAPT, single antiplatelet therapy.

References

    1. Glikson M, Wolff R, Hindricks G, et al. . EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. EuroIntervention. 2020;15(13):1133-1180. doi:10.4244/EIJY19M08_01 - DOI - PubMed
    1. Holmes DR, Reddy VY, Turi ZG, et al. ; PROTECT AF Investigators . Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542. doi:10.1016/S0140-6736(09)61343-X - DOI - PubMed
    1. Reddy VY, Sievert H, Halperin J, et al. ; PROTECT AF Steering Committee and Investigators . Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988-1998. doi:10.1001/jama.2014.15192 - DOI - PubMed
    1. Holmes DR Jr, Kar S, Price MJ, et al. . Prospective randomized evaluation of the WATCHMAN left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. doi:10.1016/j.jacc.2014.04.029 - DOI - PubMed
    1. Holmes DR Jr, Reddy VY, Gordon NT, et al. . Long-term safety and efficacy in continued access left atrial appendage closure registries. J Am Coll Cardiol. 2019;74(23):2878-2889. doi:10.1016/j.jacc.2019.09.064 - DOI - PubMed

Publication types